Tilray Brands, Inc.
TLRY
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $503.2M
$4.50
▼ -0.66%
P/E
-23.20
Mkt Cap
$503.2M
52-Wk Range
$3.67–$23.20
52-Week Range
$3.67 - $23.20
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 59.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Above-average volatility (beta 1.9).
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-8.9% over 3m
Quality
Stable
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying TLRY right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 8, 2026
JUL 28, 2026
Reported EPS of -$0.43 vs -$0.01 consensus (-3471.4% surprise). Revenue of $281.7M vs $246.3M expected (+14.4%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-3471.4%
Revenue trend · last 2Q
—
-86%
Q1 26
Q4 26
$287.8M
$41.6M
Margins · last 2Q
Gross
62.9%
Operating
-102.9%
Profit
-13.6%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Roth Capital · Apr 2, 2026
vs Industry
How TLRY stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.